Introduction {#Sec1}
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Bone metastases are a rare occurrence in gynecologic malignancies and in the majority of cases associated with a poor prognosis \[[@CR1]--[@CR8]\]. Patients (pts) are usually treated with a palliative intention to reduce pain and to preserve functionality. Complications of spinal bone metastases may be severe, especially metastatic spinal cord compression or pathological fractures may tremendously impair patients' quality of life (QoL) \[[@CR9]\].

Treatment is usually multimodal and interdisciplinary. One of the main therapy modalities for bone metastases is radiotherapy (RT). Most frequently patients are treated for pain, but existing or impending instability, neurologic symptoms due to spinal cord compression and post-surgical RT are common indications as well \[[@CR4], [@CR10]\]. The stability of vertebral bodies affected by bone metastases is an important aspect in clinical practice and for pts' QoL. On the one hand disability from pathologic fractures is risked if the vertebral column is not sufficiently stabilized, and on the other hand the usually prescribed surgical corsets add a significant immobilization to the already existing pain. However, mobilization and adequate exercises are of high importance for this subgroup of palliative pts regarding QoL \[[@CR11]\] and reduction of the time of hospitalization. Recently we reported on 338 pts with lung cancer in which a significant response towards RT in terms of stability of bone metastases was shown \[[@CR12]\].

The purpose of this analysis was to evaluate gynecologic cancer pts with spinal bone metastases treated at our department with a special focus on bone stability after RT, on prognostic factors for stability and on survival.

Methods {#Sec2}
=======

Fourty-four women with thoracic or lumbar spinal bone metastases from gynecologic malignancies were treated at the Department of Radiation Oncology at the University Hospital of Heidelberg between January 2000 and January 2012. Pts' data were collected from the Heidelberg NCT Cancer Register. The diagnosis was based on CT, MRI or bone scintigraphy findings. Bone metastases had to be located in the thoracic or lumbar spine. After 6 months 34 pts were alive and were, therefore, included in the statistical stability analysis; all 44 pts were included in the statistical survival analysis. Preexisting CT scans were reviewed regarding stability of the osteolytic lesions using the Taneichi score \[[@CR13]\]. In pts with more than one metastasis per vertebral body, the one with the worst Taneichi score was assessed. Accordingly, osteolytic metastases with subtypes A to C were classified as stable, and subtypes D to F were classified as unstable. Response was defined as a change from unstable to stable after RT at 3 or 6 months. Pts' performance status was evaluated with the Karnofsky performance status (KPS) \[[@CR14]\]. The characteristics of all pts included in this study are summarized in Table [1](#Tab1){ref-type="table"}. Median follow-up was 6.5 years.Table 1**Patients' characteristics**n%Age (years) Median (range)58 (18--85)Karnofsky PS 60%49 70%1432 80%1841 90%818Primarius Uterus1636 Ovary1432 Cervix921 Vulva49 Fallopian tube12Histology Ovaries1432  Endometrioid536  Mucinous214  Papillary serous214  Clear cell536 Fallopian tubes12  Adenocarcinoma1100 Uterus1636  Endometrioid213  Papillary serous425  Clear cell318  Leiomyosarcoma744 Cervix921  Squamous cell9100 Vulva49  Squamous cell4100Number of bone metastases Mean (range)2.1 (1--7) Solitary2352 Multiple2148Spine involvment Thoracic1534 Lumbar2455 Thoracic and lumbar511Distant metastases Brain1544 Lung2059 Liver1029 Skin13*Abbreviation*: *KPS* Karnofsky performance status.

RT was planned as virtual simulation and performed over a dorsal photon field with the energy 6 MV. PTV covered the vertebral body as well as the vertebral body immediately above and below. Median delivered dose was 30 Gy (range 20--40 Gy) in single fractions of 3 Gy (2--4 Gy) (Table [2](#Tab2){ref-type="table"}).Table 2**Treatment**Characteristicsn%Radiotherapy dose completed (Gy) Single dose (median, range)3(2--4) Cumulative dose (median, range)30(20--40)Indication for radiotherapy Pain2148 Instability1227 Neurologic614 Postoperative511Treatment for primary site Chemotherapyyes1739no2761Other treatment for bone metastases Surgical corsetyes818no3682 Bisphosphonatesyes1943no2557

Statistical analysis was done using the SAS software version 9.3 (SAS Institute, Cary, NC, USA). A p-value of p \< .05 was considered statistically significant (Chi square and Log-rank test). Overall survival was defined as the time between first diagnosis of malignancy until death from any cause, whereas bone survival was considered to be the time between first day of RT of bone metastases until death from any cause. Survival was plotted according to Kaplan and Meier. Bowker's test and kappa statistics were calculated to evaluate distribution of the Taneichi score over time. Univariate logistic regression analysis was performed to evaluate possible predictors for stability after 6 months.

Results {#Sec3}
=======

After 6 months 34 pts were alive and were assessed according to the Taneichi score prior to RT, 3 months and 6 months after RT based on CT imaging.Bone metastases were located in the thoracic spine in 34% (n = 15), in the thoracic and lumbar spine in 11% (n = 5) and in the lumbar spine in 55% (n = 24) of the pts. Most frequent subtype according to Taneichi was D (27%; n = 9) (Figure [1](#Fig1){ref-type="fig"}). Mean number of spinal metastases per patient was 2 (range 1--7). No pathological fractures occurred.Figure 1**Taneichi Score: (a) Taneichi Score of the thoracic spine, (b) Taneichi score of the lumbar spine.**

Sixteen (47%) women had unstable and 18 (53%) pts had stable bone metastases before RT. After 3 months, 62% (n = 21) of metastases were classified as stable and 85% (n = 29) after 6 months (Table [3](#Tab3){ref-type="table"}). No change from stable to unstable was observed. Taneichi subtypes improved in 44% (n = 15) and showed no change in 56% (n = 19) after 6 months. Asymmetry was apparent and correlation was good (p \< .001; kappa = .614) (Table [4](#Tab4){ref-type="table"}).Table 3**The results of Taneichi score evaluation**n%Stabilitiy before RT Unstable1647 Stable1853Stability after 3 months Unstable1338 Stable2162Stability after 6 months Unstable515 Stable2985Table 4**Test of symmetry for Taneichi-Score**Subtypes 6 months after radiotherapyABCDEFTotalSubtypes before radiotherapy**A8**000008**B**0**2**00002**C**12**5**0008**D**026**1**009**E**0011**1**03**F**00200**2**4**Total**9614212**34**This Bowker Test showed the distribution of subtypes of Taneichi-Score before and 6 month after radiation therapy. Asymmetry was apparent (p \< 0.001) and the correlation (kappa = 0.614) was good. The evaluation of the distribution of subtypes A to F showed a major change in the direction of improvement over the course of time. Deterioration occurred in no cases, improvement in 44% (n = 15). No change was seen in 56% (n = 19) of the cases.

KPS \>70% prior to RT was significantly correlated with response (p = .037). Additionally pts who did not receive chemotherapy (ChT) prior to RT were significantly more likely to respond (p = .046). Age, prescribed dose, entity of malignancy, location of spinal metastases, number of spinal metastases, bisphosphonate therapy, and use of stabilizing surgical corset were not predictive for response (Table [5](#Tab5){ref-type="table"}).Fourteen pts (32%) died during follow-up, resulting in an overall survival of 69% after 5 years and a bone survival of 73% after 1 year (Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Table 5**Response to radiotherapy after 6 months**Non responseResponsep-valuen%n%Primary malignancy0.794 Uterus975325 Ovary655545 Cervix571229 Vulva267133 Fallopian tube110000KPS0.037 ≤70%1071429 \> 70%7401360Chemotherapy prior to RT0.046 Yes1286214 No1155945Location of spinal metastases0.279 Thoracic975325 Thoracic and lumbar310000 Lumbar1158842Bisphosphonates during RT0.914 Yes1067533 No1368632Surgical corset0.523 Yes480120 No19651035Figure 2**Overall survival.** Kaplan-Meier curve of overall survival of patients with stable and unstable bone metastases.Figure 3**Bone survival.** Kaplan-Meier curve of bone survival of patients with stable and unstable bone metastases.

Discussion {#Sec4}
==========

Bone metastases are comparatively rare in gynecologic malignancies \[[@CR1]--[@CR5]\]. Pts are limited in their quality of life by severe pain and physicians concern about pathological fractures and neurologic consequences such as paraplegia. Stability of spinal metastases is a frequently raised clinical concern in this context and the Taneichi score is an established tool for classification of spinal metastases regarding risk of pathologic fracture or bone instability \[[@CR13]\]. In the thoracic spine risk factors are tumor size, and degree of costovertebral joint destruction \[[@CR15]\]. In the lumbar part of the spine tumor size and degree of pedicle destruction are the main concern \[[@CR13]\]. In our cohort almost half of the patients had unstable metastases at diagnosis. Palliative RT constitutes a potent therapeutic modality for treatment of pain and providing re-ossification \[[@CR12]\].

Stability outcome of RT in spinal metastases from gynecologic cancer is still unknown and in previous studies on spinal metastases therapeutic response was only measured in terms of pain control. We were able to demonstrate that RT is capable of improving stability due to re-ossification of osteolytic lesions; only 15% of spinal bone metastases in our cohort of women with gynecologic malignancies remained unstable 6 months after application of RT. The stability before RT was only 53%; whereas 85% were stable after RT.

ChT prior to RT was significantly associated with non-response in our analysis (p = .046). Chemotherapeutics may lead to imbalanced bone remodeling and can cause osteoporosis which in term may prevent response after RT \[[@CR16]\]. However, we cannot rule out coincidence because of the small number of pts in our analysis; especially since this is contradictive to the findings of our recent larger analysis of pts with lung cancer \[[@CR12]\]. KPS \>70% was significantly associated with response to RT (p = .037) which may be explained by continued physical strain to the bones in mobile pts \[[@CR17], [@CR18]\].

Overall survival and bone survival were poor and coincide with results from the literature. The longest reported overall survival and bone survival in the literature were 46 months and 25 months respectively \[[@CR1]--[@CR8]\].

Conclusion {#Sec5}
==========

RT is an effective palliative treatment of spinal bone metastases and is capable of improving stability in pts with gynecologic malignancies. KPS may be a predictor for positive response to RT. Pts who underwent ChT prior to RT may require additional bone supportive treatment (bisphosphonates, denosumab, calcium and vitamin D) to overcome bone remodeling imbalance. Survival in pts with bone metastases remains low.
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